Study shows balloon pump use prior to angioplasty does not reduce heart muscle damage

August 30, 2011

Inserting intra-aortic balloon pumps prior to angioplasty in patients with acute myocardial infarction (AMI) does not reduce the scope of heart muscle damage, a condition referred to as infarct size, according to a new study conducted by Duke University Medical Center researchers.

The findings were published online today in the (JAMA), and presented at the in Paris, France.

The intra-aortic balloon pump works by increasing the blood supply to the heart, which reduces the heart's workload. According to Manesh Patel, M.D., the principal investigator and cardiologist at the Duke Clinical Research Institute (DCRI), "animal studies had suggested that inserting a balloon pump before opening the vessel would reduce the heart's workload and by doing so, could potentially reduce infarct size When we tested this observation in humans, we did not show an infarct reduction."

CRISP AMI was a multi-center, prospective, randomized trial that enrolled patients with acute ST-segment elevation (STEMI) without shock within six hours of chest pain onset and planned primary (PCI). Of the 337 patients enrolled, 161 were randomized to receive intra-aortic balloon counterpulsation (IABC) prior to primary PCI, and 176 to the standard of care (SOC), which is primary PCI without IABC support.

The mean infarct size, measured using cardiac , was not significantly different between the IABC and SOC groups (42.1% vs. 37.5%). At 30 days, major bleeding or transfusion occurred in 5 (3.1%) of the IABC patients versus 3 (1.7%) of SOC patients. Major vascular complications occurred in 7 (4.3%) of the IABC patients, versus 2 (1.1%) of the SOC patients. treated with IABC compared to SOC. By six months, death occurred in 3 (1.9%) in the IABC group and 9 (5.2%) in the SOC group.

While the study was not set up to report clinical events, the researchers say the results are interesting because they offer unique insight into treating AMI patients.

"The most striking observation is the excellent overall outcome for the highest-risk patients within the context of this trial," says E. Magnus Ohman, M.D., a co-investigator and cardiologist at DCRI. "The IABC group had less than five percent mortality. It's hard to improve that. We've gotten very good at treating AMI patients."

patients represent nearly half of the approximately 1.5 million annual hospitalizations for acute coronary syndromes in the U.S. Acute mortality risk is between 6% and 15%; one-year mortality is estimated at 38% for women and 25% for men.

Ohman says it's also important to note that 15 of the patients in the standard of care group crossed over to receive IABC – five prior to PCI and 10 after.

"While routine use of IABC is not recommended, physicians should be vigilant about identifying who are at risk for rapid deterioration and may benefit from counterpulsation," says Patel.

Explore further: Study examines outcomes of erythropoietin use for heart attack patients undergoing PCI

Related Stories

Recommended for you

Resveratrol reverses heart damage in mice with Chagas disease

October 27, 2016

Resveratrol is the antioxidant found in red wine and famous as a food supplement capable of mimicking the effects of exercise and low calorie diets in the heart. Now Vilar-Pereira and colleagues show that treatment with resveratrol ...

Cholesterol test for one-year-olds? Study says it could help

October 26, 2016

What if a blood test could reveal that your child is at high risk for early heart disease years in the future, giving you a chance to prevent it now? A big study in England did that—screening thousands of babies for inherited ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.